Bioclin Therapeutics Inc., a startup developing a monoclonal antibody (MAb) to fight metastatic bladder cancer, has expanded its series B financing to $50 million. Proceeds from the round will be used to support phase II testing of the company's lead candidate, B-701, both as a single agent as well as in combination with Keytruda (pembrolizumab, Merck & Co. Inc.) and separately with docetaxel. Enrollment in phase II trials of the anti-fibroblast growth factor receptor-3 (FGFR3) MAb is expected to wrap up by the second half of 2018, with initial data expected by year-end, said Stephen Lau, CEO of the San Leandro, Calif.-based venture.